文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

阿帕替尼治疗晚期或复发性宫颈癌:开放标签随机对照试验研究方案

Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial.
PubMed 文献 · Trials · 2018-09-17

本研究为一项在中国开展的随机、平行组、开放标签Ⅱ期临床试验,计划纳入60例晚期或复发性宫颈癌患者,按1:1意向分配至阿帕替尼试验组或对照组,主要终点为无进展生存期,次要终点包括总生存期、疾病控制率、客观缓解率、生活质量及不良事件,旨在验证阿帕替尼的疗效与安全性。

要点

  • 阿帕替尼是一种口服VEGFR-2小分子抑制剂,已在多种实体瘤中显示生存获益。
  • 本试验计划纳入60例晚期或复发性宫颈癌患者,1:1随机分配至试验组或对照组。
  • 主要终点为无进展生存期,次要终点包括总生存期、疾病控制率、客观缓解率、生活质量及不良事件。

核心结论

  • 本试验旨在验证阿帕替尼治疗晚期或复发性宫颈癌的疗效与安全性。

研究设计与样本

  • 研究为随机、平行组、开放标签、干预性Ⅱ期临床试验,计划纳入60例晚期或复发性宫颈癌患者,按1:1意向分配至试验组或对照组。
  • 评估在入组前(基线)及治疗后每4周进行。

关键数值与推荐

  • 主要终点为无进展生存期。
  • 次要终点包括总生存期、疾病控制率、客观缓解率、生活质量及不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In China, cervical cancer is the fifth most commonly diagnosed cancer, and the outcomes for patients with advanced or recurrent disease are poor. Apatinib, a small molecule inhibitor of vascular endothelial growth factor receptor (VEGFR-2), is an orally bioavailable agent, which has shown survival benefit in multiple solid tumors. Based on previous research, this phase II clinical trial aims to verify apatinib's efficacy and safety in patients with advanced or recurrent cervical cancer. METHODS/DESIGN: This randomized, parallel arm, open-label, interventional trial will be carried out to evaluate the efficacy and the safety of apatinib for advanced or recurrent cervical cancer. A total of 60 eligible patients will be allocated by intention, in a ratio of 1:1, to either the experimental group or the control group. The primary endpoint is progression-free survival, the secondary endpoints include overall survival, disease control rate, objective response rate, quality of life, and adverse events. Assessments will be carried out before enrolment (baseline) and every 4 weeks after treatment. DISCUSSION: The aim of this trial is to demonstrate the clinical effect, safety, and side effects of apatinib in the treatment of advanced or recurrent cervical cancer. This study will clarify the efficacy and safety of this regimen. TRIAL REGISTRATION: Chinese Clinical Trials Registry, ChiCTR-OIN-17012164 . Registered on 24 July 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhou JG, Zhou NJ, Zhang Q, et al. Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial. Trials. 2018. PMID: 30223869. doi:10.1186/s13063-018-2858-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。